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BACKGROUND & AIMS: Pancreatitis is the most important risk
factor for pancreatic ductal adenocarcinoma (PDAC). Pancrea-
titis predisposes to PDAC because it induces a process of acinar
cell reprogramming known as acinar-to-ductal metaplasia
(ADM)—a precursor of pancreatic intraepithelial neoplasia
lesions that can progress to PDAC. Mutations in KRAS are found
at the earliest stages of pancreatic tumorigenesis, and it ap-
pears to be a gatekeeper to cancer progression. We investigated
how mutations in KRAS cooperate with pancreatitis to promote
pancreatic cancer progression in mice. METHODS: We gener-
ated mice carrying conditional alleles of Yap1 and Taz and
disrupted Yap1 and Taz using a Cre-lox recombination strategy
in adult mouse pancreatic acinar cells (Yap1ﬂ/ﬂ;Tazﬂ/ﬂ;Ela1-
CreERT2). We crossed these mice with LSL-KrasG12D mice,
which express a constitutively active form of KRAS after Cre
recombination. Pancreatic tumor initiation and progression
were analyzed after chemically induced pancreatitis. We
analyzed pancreatic tissues from patients with pancreatitis or
PDAC by immunohistochemistry. RESULTS: Oncogenic activa-
tion of KRAS in normal, untransformed acinar cells in the
pancreatic tissues of mice resulted in increased levels of
pancreatitis-induced ADM. Expression of the constitutive active
form of KRAS in this system led to activation of the transcrip-
tional regulators YAP1 and TAZ; their function was required for
pancreatitis-induced ADM in mice. The JAK–STAT3 pathway
was a downstream effector of KRAS signaling via YAP1 and
TAZ. YAP1 and TAZ directly mediated transcriptional activation
of several genes in the JAK–STAT3 signaling pathway; this
could be a mechanism by which acinar cells that express
activated KRAS become susceptible to inﬂammation.
CONCLUSIONS:We identiﬁed a mechanism by which oncogenic
KRAS facilitates ADM and thereby generates the cells that
initiate neoplastic progression. This process involves activation
of YAP1 and TAZ in acinar cells, which up-regulate JAK–STAT3
signaling to promote development of PDAC in mice.Abbreviations used in this paper: ADM, acinar-to-ductal metaplasia; CMV,
cytomegalovirus; ES, embryonic stem cell; HBSS, Hank’s balanced salt
solution; IL, interleukin; PanIN, pancreatic intraepithelial neoplasia; PBS,
phosphate-buffered saline; PDAC, pancreatic ductal adenocarcinoma;
TGFa, transforming growth factor–a.
Most current articleKeywords: PanINs; Pancreatic Cancer Progression; Mouse
Model; Inﬂammation.
he most common and lethal tumor of the pancreas,© 2016 by the AGA Institute
0016-5085/$36.00
http://dx.doi.org/10.1053/j.gastro.2016.05.006Tpancreatic ductal adenocarcinoma (PDAC), exhibits
the histologic morphology and marker expression of
pancreatic duct cells. However, many of these tumorsoriginate from the other major exocrine cell type, acinar
cells, through a reprogramming process known as acinar-to-
ductal metaplasia (ADM).1 ADM is characterized by a change
in marker expression: acinar cells positive for amylase also
begin to express the ductal cell marker CK19. These poorly
differentiated cells express the pancreatic progenitor cell
markers Pdx1 and Nestin2,3 and are important precursors of
malignancy.4 Pancreatic intraepithelial neoplasia (PanIN)
lesions have a well-established histologic progression to-
ward PDAC,5 and can arise from ADM lesions.1 ADM is the
earliest pre-neoplastic lesion that predisposes to PDAC,
making acinar-to-ductal reprogramming a crucial step in
pancreatic cancer initiation.
KRas mutations are found in >90% of all PDAC cases6
and they occur early, in low-grade pre-neoplastic le-
sions.7,8 Although the importance of KRas mutation in the
development of ADM, PanIN, and pancreatic tumors is well
established,9 the mechanisms by which oncogenic Ras leads
to PDAC are not fully understood.
Pancreatitis is a well-known risk factor for PDAC devel-
opment in humans. Patients with hereditary pancreatitis
show a 50-fold increase in pancreatic cancer incidence.10 In
mouse models, both acute and chronic inﬂammation of the
pancreas accelerate pancreatic cancer progression.1,11
Pancreatitis can be induced experimentally by injection of
caerulein, which induces acinar cell death and inﬂamma-
tion.12 In caerulein-induced pancreatitis, inﬂammation in-
duces acinar cells to reprogram to form ADM lesions,11
which may be transient, or in the presence of a KRasG12D
mutation, persistent.13 Transforming growth factor–a
(TGFa) administration or overexpression also cooperates
with KRasG12D to induce ADM in vitro.3,14 Pancreatic
inﬂammation facilitates tumorigenesis by inducing ADM.
Expression of oncogenic KRasG12D at endogenous levels
in acinar cells triggers progression to pancreatic adenocar-
cinoma very inefﬁciently. Stronger transgenic expression of
oncogenic Ras,15 or additional oncogenic stimuli, such as
September 2016 Regulation of Acinar-to-Ductal Reprogramming by KRas 527mutant p5316 or TGFa overexpression,17 are required. Many
of these additional stimuli directly or indirectly increase Ras
activity, suggesting that a positive feedback loop amplifying
oncogenic Ras signaling is required for PDAC progression.18
The reliance of established PDAC tumors on KRasG12D
expression can be alleviated by up-regulation of the tran-
scriptional regulator YAP1.19 YAP1 has also been implicated
in progression from PanIN to PDAC,20 but its contribution at
the reprogramming stage is unclear.
Here we show that KRas mutation sensitizes acinar
cells to reprogramming by activating YAP1 and TAZ
signaling, which in turn up-regulates components of the
JAK–STAT3 pathway. This increases sensitivity to inﬂam-
matory stimuli, which induces widespread ADM among
KRas-mutant acinar cells. Importantly, inhibiting KRasG12D-
and pancreatitis-induced reprogramming by inactivating
YAP1/TAZ also prevents progression to PanIN, high-
lighting the importance of this mechanism for pancreatic
cancer initiation.BA
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Mouse Lines
For the generation of conditional Yap1 and Taz/Wwtr1
knockout mice, embryonic stem (ES) cell clones carrying the
respective targeted alleles were obtained from the Knockout
Mouse Project (KOMP) Repository (Yap1<tm1a(KOMP)
Mbp>; ES clone E08) and the European Conditional Mouse
Mutagenesis (EUCOMM) Program (Wwtr1<tm1a(EUCOMM)
Wtsi>; ES clone A08). Targeted ES cell clones (agouti
C57BL/6 parental cell line JM8A3.N1) were injected into
blastocysts of C57BL/6 background to generate chimeric
mice, which were then crossed with Flpo-expressing mice
(Tg(CAG-Flpo)1Afst; C57BL/6 background)21 to remove the
neo-selection cassette and obtain mice carrying the condi-
tional ﬂoxed alleles Yap1<tm1c(KOMP)Mbp> and
Wwtr1<tm1c(EUCOMM)Wtsi> isogenic on C57BL/6. The
Flpo-allele was bred out and mice were maintained on a
C57BL/6 background. For genotyping and validation of
knockout alleles, see Supplementary Figure 4 and
Supplementary Materials and Methods.
The Stat3ﬂ/ﬂ, Pdx1-Cre, R26-LSL-YFP, LSL-KRasG12D, and
Ela1-CreERT2 mouse lines have been described (see
Supplementary Materials and Methods).
Acute Pancreatitis Induction
Acute pancreatitis in C57BL/6 mice was induced by 8
intraperitoneal injections of caerulein (Sigma-Aldrich, St Louis,
MO) dissolved in phosphate-buffered saline (PBS) given at
1-hour intervals on 2 consecutive days at a dose of 50 mg/kg
body weight per injection (high dose). Other strains received a
similar treatment schedule except with 6 injections at a dose of
40 mg/kg body weight per injection (low dose). Control animals
received injections of PBS only.
Gene Set Enrichment Analysis
Gene set enrichment analysis was performed on the pub-
lished transcription proﬁle of C57BL/6 Jackson mice treated
with caerulein or PBS22 and on the transcription proﬁle ofmouse liver organoids overexpressing YAP1,23 with the soft-
ware developed by the Broad Institute of the Massachusetts
Institute of Technology and Harvard University. The settings
are listed in Supplementary Materials and Methods.Primary Acinar Cell Culture
Mice were sacriﬁced by cervical dislocation, the pancreas
was dissected out and transferred to ice-cold Hank’s balanced
salt solution (HBSS) supplemented with penicillin/strepto-
mycin (Sigma-Aldrich). Pancreata were cut into small pieces
and digested with 2 mg/mL Collagenase P (Roche Diagnostics,
Indianapolis, IN) in HBSS for 15 minutes at 37C. Cells were
washed 3 times with HBSS supplemented with 5% fetal bovine
serum and then ﬁltered through 500-mm and 105-mm nylon
meshes (Spectrum Laboratories, Rancho Dominguez, CA). The
cell suspension was layered on top of 30% fetal bovine serum
in HBSS, centrifuged at 1000 rpm for 2 minutes and the cell
pellet was resuspended in acinar cell culture medium ([Way-
mouth’s medium; Life Technologies, Carlsbad, CA] supple-
mented with 1% fetal bovine serum, penicillin/streptomycin
[Sigma-Aldrich], 1 mg/mL dexamethasone [Sigma-Aldrich] and
100 mg/mL soybean trypsin inhibitor [Sigma-Aldrich]). The cell
suspension was then infected with adenoviruses either
obtained from the University of Iowa Carver College of Medi-
cine (Ad5-GFP and Ad5-Cre-GFP), at a concentration of 1.25 
107 plaque-forming units/mL, or generated by cloning (Ad-GFP,
Ad-GFP-YAP1-5SA, and Ad-GFP-TAZ-S89A), at a concentration
of 5  105 plaque-forming units/mL. Acinar cells were incu-
bated with adenoviruses for 1 hour at 37C. Six-well tissue
culture plates were coated with an 800 mL layer of collagen
solution (4 mg/mL rat tail collagen; BD Biosciences, San Jose,
CA), 10% 10 Waymouth’s medium (Sigma-Aldrich) and 0.02
mol/L NaOH; Sigma-Aldrich). The cell suspension was mixed
1:1 with collagen solution and plated onto the collagen layer.
The acinar cell/collagen mix was allowed to solidify for 1 hour
at 37C before adding medium. Medium was changed on day 1
and day 3 after the isolation. Quantiﬁcations were done on day
5 after isolation. To harvest the cells, the collagen matrix was
digested with 1 mg/mL collagenase P (Roche Diagnostics)
diluted in HBSS for 30 minutes at 37C.Production of Recombinant Adenoviruses
The vectors harboring the coding sequences of the phos-
phorylation mutants of YAP1 (5SA) and TAZ (S89A), kindly
provided by S. Piccolo, were used to subclone the YAP1 and
TAZ complementary DNAs in the pAd-Track-cytomegalovirus
(CMV) vector (Addgene, Cambridge, MA; #16405). This re-
sults in the expression of YAP1/TAZ under the control of the
CMV promoter and pAd-Track-CMV empty vector was used as
control. The pAd-Track-CMV contains a GFP complementary
DNA under control of a second CMV promoter. Recombinant
adenoviruses expressing GFP, YAP1-5SA in combination with
GFP or TAZ-S89A in combination with GFP were generated
following the protocol as described.24 Brieﬂy, human HEK293A
cells were co-transfected with pAd-Easy-1 (Addgene #16400)
together with pAd-Track-CMV, pAd-Track-CMV-YAP1-5SA, or
pAd-Track-CMV-TAZ-S89A. Adenoviruses were harvested 14
days after transfection. To generate higher viral titer, fresh
HEK293A were infected with the adenoviruses and grown for 7
days before harvesting and this process was repeated 3 times.
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tion Kit (TaKaRa Clontech, Mountain View, CA) according to the
manufacturer’s protocol. Virus titers were determined by
infecting HEK293T cells with a dilution series of the adenovi-
ruses. After infection, cells were overlaid with agarose and
plaques were visualized by MTT (Sigma-Aldrich) and quantiﬁed
7 days later. This protocol generated virus titer ranging from 1
to 6  108 plaque-forming units/mL.
Immunoblot Analysis and Ras-GTP
Pulldown Assay
Protein lysates were obtained from dissected pancreata, pri-
mary acinar cells or PANC1 cells and homogenized in Cell Lysis
Buffer (Cell Signaling, Danvers, MA) containing proteasome in-
hibitor (Sigma-Aldrich). Immunoblots were performed as
described.25 Polyvinylidene diﬂuoride membranes (GE Health-
care, Little Chalfont, Buckinghamshire, United Kingdom) were
incubated with antibodies against YAP1 (Cell Signaling; #4912
and Santa Cruz Biotechnology, Santa Cruz, CA; sc-15407); p-YAP1
(Ser127 in humans and Ser112 in mice; Cell Signaling; #4911);
TAZ (Sigma-Aldrich; HPA007415); CK19 (DHSB; TROMA-III);
STAT3 (Cell Signaling; #4904); p-STAT3 (Tyr705; Cell Signaling;
#9131); LATS1 (Cell Signaling; #3477); p-LATS1 (Ser909; Cell
Signaling; #9157); LIFR (Santa Cruz Biotechnology; sc-659);
PDX1 (R&D Systems, Minneapolis, MN; MAB2419); SOX9
(Millipore, Billerica, MA; AB5535); p-Erk1/2 (Thr202/Tyr204;
Cell Signaling; #9106); Erk1/2 (Cell Signaling, #9102); glyceral-
dehyde-3-phosphate dehydrogenase (Abcam, Cambridge, MA;
ab9485); and ACTIN (Abcam; ab49900). Active Ras levels were
determined by Ras-GTP pull-down assay (ThermoFisher Scienti-
ﬁc, Logan, UT) using the Raf Ras-binding-domain fused to GST
(Raf-RBD-GST) according to the manufacturer’s instructions.
Signal intensities of bandswere quantiﬁed using ImageJ software.
Statistics
Statistical analysis was performed using GraphPad Prism
6.0a software (GraphPad, La Jolla, CA) and 2-tailed Student t
tests were used to generate P values. Normalized enrichment
scores and nominal P values for the gene set enrichment
analysis were generated using the software developed by the
Broad Institute of the Massachusetts Institute of Technology
and Harvard University. P < .05 was considered signiﬁcant.
Study Approval
Mouse experiments were carried out with the approval of
the London Research Institute’s Ethical Review Committee
according to the UK Animals (Scientiﬁc Procedures) Act 1986.
Results
YAP1 and TAZ Are Up-Regulated in Pancreatitis
ADM caused by pancreatitis is an initiating step in
pancreatic tumor development.1 To ﬁnd molecular regula-
tors of this process, we performed gene set enrichment
analysis26 on the published transcriptional proﬁle of mouse
pancreata treated with caerulein22 to identify pathways up-
regulated in pancreatitis (Supplementary Figure 1A). Many
of these pathways, such as Wnt, Notch, and JAK–STAT3, have
previously been implicated in either acinar cell regenerationor in inducing ADM upon injury.13,27–29 Intriguingly, the
highest gene set enrichment scores were for YAP1 target
genes (Figure 1A and Supplementary Figure 1A).
To investigate a possible role for YAP1/TAZ signaling in
pancreatitis-induced ADM, we treated C57BL/6 mice with
caerulein to induce pancreatitis (Figure 1B). In untreated
mice, YAP1 and TAZ proteins showed nuclear localization in
duct cells of the pancreas, with low or absent expression in
acinar cells and islet cells20,30 (Supplementary Figure 1B).
Consistent with the gene set enrichment analysis, the YAP1/
TAZ target genes Ctgf, Cyr61, Ankrd1, and Amotl2 were
overexpressed in caerulein-treated animals compared with
control PBS-treated mice (Figure 1C). Caerulein treatment
reduced activatory phosphorylation of the YAP1/TAZ
inhibitory kinase Lats1 (Figure 1D and Supplementary
Figure 2A and B). In line with this, we observed increased
YAP1 and TAZ protein levels (Figure 1D and Supplementary
Figure 2A and B), accompanied by strong nuclear localiza-
tion, indicating more active YAP1/TAZ in caerulein-treated
animals (Figure 1E). Levels of the duct cell marker CK19
were also increased, consistent with acinar-to-ductal
reprogramming (Figure 1D and Supplementary Figure 2A
and B). To determine the identity of the YAP1/TAZ-
responsive cells, we performed immunoﬂuorescence co-
staining with pancreatic cell type speciﬁc markers. Cells
coexpressing CK19 and the acinar cell marker amylase
showed high levels of nuclear YAP1 and TAZ, with some
stromal cells also positive (Figure 1F). Thus, YAP1/TAZ
activity is elevated in the injured, inﬂamed pancreas,
particularly in the subset of cells undergoing ADM.
YAP and TAZ Are Up-Regulated in Acinar-to-
Ductal Metaplasia Lesions Induced by KRasG12D
We next asked whether YAP1/TAZ up-regulation is
restricted to caerulein-induced ADM or also occurs during
ADM induced by oncogenic Ras. The pancreatic tumor
mouse model LSL-KRasG12D;Pdx1-Cre develops PDAC with
long latency and displays the whole spectrum of pre-
neoplastic lesions31 (Figure 2A). We found a strong signal
for both YAP1 and TAZ in ADM lesions of these mice, and an
up-regulation of YAP1 and TAZ in pancreatic protein lysates
(Figure 2A and B and Supplementary Figure 3A and B).
Analysis of YAP1 and TAZ immunostaining on human
pancreatic tissue microarrays showed strong up-regulation
of YAP1 in human ADM and PanIN pre-neoplastic lesions
compared with normal acini (Figure 2C–E). TAZ was
strongly up-regulated in ADM and to a lesser extent in
PanIN lesions in mouse models and human tissues
(Figure 2A and C–E). Surprisingly, we found a signiﬁcant
down-regulation of YAP1 and TAZ protein levels in human
PDAC samples compared with ADM lesions (Figure 2C–E),
suggesting a functional role of YAP1 and TAZ particularly
during tumor initiation.
YAP1 and TAZ Are Necessary and Sufﬁcient for
Acinar-to-Ductal Metaplasia Induction
To determine the functional requirement for YAP1/TAZ
signaling in acinar-to-ductal reprogramming, we generated
Figure 1. YAP1 and TAZ
are up-regulated in
pancreatitis. (A) Gene set
enrichment analysis of
transcription data from
caerulein-treated pan-
creata22 identiﬁed enrich-
ment of the conserved
YAP1 signatures reported
by Yimlamai et al23 and
Cordenonsi et al.47 Nor-
malized enrichment score
(NES) and nominal (NOM)
P values are shown. (B)
Scheme showing model of
caerulein-induced acute
pancreatitis in C57BL/6
mice. (C) Quantitative
reverse transcription poly-
merase chain reaction of
YAP1/TAZ target genes in
caerulein-treated vs PBS-
treated pancreata. n ¼ 3
mice each group; means ±
SEM are shown; ***P <
.005, Student t test. (D)
Immunoblots of pancreas
lysates from caerulein-
and PBS-treated animals.
p-Lats1, phosphorylated
Lats1 (Ser909); p-Yap1,
phosphorylated Yap1
(Ser112). (E) Immunohis-
tochemical stains of YAP1
and TAZ in pancreata of
caerulein- and PBS-
treated mice. Scale
bars ¼ 50 mm. n ¼ 5–7
mice analyzed. (F) Triple
immunoﬂuorescence of
pancreata from caerulein-
and PBS-treated animals
showing the duct marker
CK19, the acinar marker
amylase and either YAP1
or TAZ. Arrowheads indi-
cate ADM cells. Scale
bars ¼ 20 mm. n ¼ 5–7
mice analyzed. DAPI, 40,6-
diamidino-2-phenylindole
dihydrochloride.
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(Supplementary Figure 4A–F). YAP1 and TAZ were efﬁ-
ciently deleted in Yap1ﬂ/ﬂ;Tazﬂ/ﬂ primary acinar cells
(Supplementary Figure 5A and B). We combined the ﬂoxed
Yap1ﬂ/ﬂ and Tazﬂ/ﬂ alleles with the Cre-inducible oncogenicLSL-KRasG12D allele, shown to induce ADM in cultured acinar
cells,14 and assayed ADM in vitro (Figure 3A). As expected,
Cre-mediated activation of KRasG12D transformed acinar cell
clusters into tubular duct-like structures (Figure 3B). Deletion
of Yap1 signiﬁcantly reduced the ability of KRasG12D to induce
Figure 2. YAP1 and TAZ
are up-regulated in ADM
lesions induced by
KRasG12D. (A) Immunohis-
tochemical analysis of
YAP1 and TAZ in normal
(LSL-KRasG12D) pancreas
and pancreas from 6-
month-old LSL-KRasG12D;
Pdx1-Cre mice. Scale
bars ¼ 50 mm. Dotted lines
highlight mouse PanIN le-
sions. n ¼ 4–5 mice
analyzed. (B) Immunoblot
analysis of pancreas
lysates from control LSL-
KRasG12D and LSL-
KRasG12D;Pdx1-Cre mice.
p-Lats1, phosphorylated
Lats1 (Ser909); p-Yap1,
phosphorylated Yap1
(Ser112). (C) Immunohis-
tochemical analysis of
YAP1 and TAZ on human
pancreatic tissue micro-
arrays. Scale bars ¼ 50
mm. (D, E) Quantiﬁcation of
immunohistochemical
staining intensity, ranging
from absent (0) to highest
(6) for YAP1 (D) and TAZ
(E) on human pancreatic
tissue microarrays. n ¼
number of tissue cores.
Means ± SD are shown.
**P < .01; ***P < .005,
Student t test.
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Yap1/Taz acinar cells, KRasG12D failed to induce ADM
(Figure 3B and Supplementary Figure 5C and D).
To address the requirement for YAP1 in vivo, we com-
bined Yap1ﬂ/ﬂ with the Pdx1-Cre mouse line. Caerulein-
induced ADM lesions co-expressing CK19 and amylase
were readily observed in Yap1ﬂ/ﬂ;Pdx1-Cre mice. However,
these lesions were positive for YAP1 nuclear staining(Supplementary Figure 6A), suggesting that ADM occurred
in cells that had escaped Yap1 deletion. Consistent with this,
polymerase chain reaction and immunoblot analysis showed
that the recombination efﬁciency and consequent depletion
of YAP1 was incomplete in Yap1ﬂ/ﬂ;Pdx1-Cre mice
(Supplementary Figure 6B and C). As an alternative model,
we used a tamoxifen-inducible Cre line under the control of
the acinar-speciﬁc Ela1 promoter (Ela1-CreERT2) in
Figure 3. YAP1 and TAZ are necessary and sufﬁcient for ADM induction. (A) Scheme showing in vitro assay for KRasG12D-
induced ADM. (B) Brightﬁeld images of pancreatic acinar cell clusters on day 5 after isolation from LSL-KRasG12D and LSL-
KRasG12D;Yap1ﬂ/ﬂ;Tazﬂ/ﬂ mice. Cells were infected with adenoviruses encoding either GFP (Ad-GFP) or GFP plus Cre (Ad-Cre)
on day 0. White arrows: tubular ductal structures. Scale bars ¼ 50 mm. Quantiﬁcation of tubular ductal structures of the
indicated genotypes with n ¼ 3–4 mice per group; means ± SEM are shown; ***P < .005, n.s., not signiﬁcant, Student t test. (C)
Experimental design of caerulein-induced acute pancreatitis in the acinar-speciﬁc and tamoxifen-inducible Ela1-CreERT2mouse
model combined with the R26-LSL-YFP lineage tracer. (D) Triple immunoﬂuorescence of pancreata from R26-LSL-YFP;Ela1-
CreERT2 and R26-LSL-YFP;Yap1ﬂ/ﬂ;Tazﬂ/ﬂ;Ela1-CreERT2 mice treated with caerulein as indicated in (C). Scale bars ¼ 20 mm.
Dotted white lines indicate ADM lesions. Quantiﬁcation of GFP-positive ADM cells (CK19/amylase double-positive) as a per-
centage of total GFP-positive cells in caerulein-treated mice of the indicated genotypes. n ¼ 3 mice per group; means ± SEM
are shown; **P < .01, Student t test. (E) Scheme showing in vitro assay for YAP1 and TAZ-induced ADM. (F) Brightﬁeld images
(upper panels) and GFP signal (lower panels) of acinar cells after 5 days in culture, infected on day 0 with Ad-GFP, Ad-YAP1-
5SA-GFP, or Ad-TAZ-S89A-GFP. Scale bars ¼ 25 mm. Quantiﬁcation of GFP-positive tubular ductal structures at day 5, in n ¼ 3
experiments; means ± SEM are shown; ***P < .005, Student t test. DAPI, 40,6-diamidino-2-phenylindole dihydrochloride.
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Figure 4. YAP1/TAZ activation controls JAK-STAT3 signaling via transcription of STAT3. (A) Quantitative reverse transcription
polymerase chain reaction (RT-PCR) of the indicated genes and immunoblots of lysates from PANC1 cells expressing short-hairpin
RNAs (shRNAs) against YAP1 and TAZ (shYAP/TAZ-#1 and -#2) or non-targeted shRNA control (shNT). n ¼ 3; means ± SEM
shown. (B) Immunoblots of primary acinar cell lysates 2 days after isolation and infection with Ad-GFP, Ad-YAP1-5SA-GFP, or
Ad-TAZ-S89A-GFP. (C) Quantitative chromatin immunoprecipitation PCR of the LIFR, GP130, and STAT3 loci (promoter and intron
regions) using either IgG or an antibody against TEAD4. ZFP37 intron ¼ negative control region; CTGF promoter ¼ positive control
region. n¼ 3 experiments; means± SEM shown. (D) Scheme showing luciferase expression construct with human STAT3 promoter
region.Basepair (bp) numbers indicateposition relative toSTAT3 transcriptionstart site.Redbox indicatesGT-IIcTEADbindingmotif;
genomic sequence ofWTGT-IIc shown below. Mutant STAT3 promoter construct with a 6-bp deletion of the GT-IIc site (mut GT-IIc)
was used as control. Luciferase expression analysis usingwild-type andmutant STAT3 promoter regions in AR42J acinar cells 1 day
after transfection with empty vector, YAP1-5SA, or TAZ-S89A. An artiﬁcial TEAD luciferase reporter consisting of 8 GT-IIc motifs was
used as positive control. n ¼ 3–5 experiments; means ± SEM shown. (E) Immunohistochemistry showing phosphorylated STAT3
(Tyr705) in pancreata of caerulein- and PBS-treated C57BL/6 mice. Scale bars ¼ 50 mm. n ¼ 3 mice analyzed. (F) Immunoblots of
pancreas lysates fromPBS-andcaerulein-treatedanimalsonday2andday7after treatment. p-Stat3,phosphorylatedStat3 (Tyr705).
Quantitative RT-PCR of JAK–STAT3 pathway genes in caerulein-treated vs PBS-treated pancreata 2 days after treatment. n ¼ 3–4
mice per group; means ± SEM shown. *P< .05; **P < .01; ***P< .005, n.s., not signiﬁcant, Student t test.
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Figure 5. YAP1 and TAZ
are required for KRasG12D-
induced ADM in vivo in
response to pancreatitis.
(A) Scheme showing
experimental design of
caerulein-induced acute
pancreatitis in cooperation
with acinar-speciﬁc
KRasG12D mutation. (B)
H&E stain and amylase
and CK19 antibody stains
of pancreata from mice of
the indicated genotypes.
Scale bars: H&E (top
row) ¼ 2 mm; (2nd row) ¼
200 mm; (3rd row) ¼ 50
mm; amylase ¼ 200 mm;
CK19 (5th row) ¼ 200 mm;
(6th row) ¼ 50 mm; double
immunoﬂuorescence ¼ 50
mm. (C) Quantiﬁcation of
CK19þamylaseþ ADM
pancreatic area in pancre-
atic sections of the geno-
types shown in (B). n ¼ 3
mice per genotype; means
± SEM are shown; ***P <
.005, Student t test.
(D) Immunoblots of
pancreas lysates from
mice of the indicated
genotypes treated as
shown in (A). DAPI, 40,6-
diamidino-2-phenylindole
dihydrochloride.
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allow identiﬁcation of recombined cells (Figure 3C). In this
model, GFP-positive acinar cells that had lost both Yap1 and
Taz were signiﬁcantly impaired in caerulein-induced ADM
formation (Figure 3D), supporting a requirement for YAP1
and TAZ in ADM formation in vivo. Importantly, co-deletion
of Yap1 and Taz did not affect acinar cell viability
(Supplementary Figure 7A).
We next examined the effects of ectopic YAP1/TAZ
activation in acinar cells by generating adenoviral vectors
encoding constitutively active phosphorylation mutants of
YAP1 (Ad-GFP-YAP1-5SA) and TAZ (Ad-GFP-TAZ-S89A)
(Supplementary Figure 7B–D). These mutants are predom-
inantly nuclear and able to induce target gene expres-
sion32,33: as expected, adenoviral delivery of YAP1-5SA, as
well as TAZ-S89A, resulted in up-regulation of their target
genes Ctgf and Cyr61 in primary acinar cells (SupplementaryFigure 7E). Strikingly, acinar explants infected with either
Ad-GFP-YAP1-5SA or Ad-GFP-TAZ-S89A, but not Ad-GFP,
underwent conversion to a duct cell morphology
(Figure 3E and F). These data suggest that activation of the
transcriptional regulators YAP1 and TAZ in acinar cells is
sufﬁcient to induce ADM.YAP1/TAZ Activation Increases Expression of
JAK–STAT3 Pathway Components
To investigate the molecular mechanisms downstream of
YAP1/TAZ, we analyzed the published transcription proﬁle
of cells overexpressing YAP1.23 Gene set enrichment analysis
of BIOCARTA-annotated pathways in this dataset34 identiﬁed
the interleukin (IL)6–JAK–STAT3 signaling cascade as
strongly regulated by YAP1 overexpression (Supplementary
Figure 8A). Importantly, JAK–STAT3 signaling was also
Figure 6. KRasG12D- and caerulein-mediated activation of STAT3 depends on YAP1 and TAZ. (A) Quantitative reverse tran-
scription polymerase chain reaction of the YAP1/TAZ target genes Ctgf, Cyr61, and Amotl2 and the STAT3 pathway genes
Stat3, Lifr, and Gp130 in pancreas lysates from Ela1-CreERT2, LSL-KRasG12D;Ela1-CreERT2 and LSL-KRasG12D;Yap1ﬂ/ﬂ;Tazﬂ/
ﬂ;Ela1-CreERT2 mice 7 days after the last tamoxifen injection. n ¼ 3–5 mice per genotype; means ± SEM are shown; *P < .05;
**P < .01; n.s., not signiﬁcant, Student t test. (B) Immunoblot analysis of primary acinar cells from wild-type (WT), LSL-
KRasG12D and LSL-KRasG12D;Yap1ﬂ/ﬂ;Tazﬂ/ﬂ mice, 2 days after isolation and infection with Ad-Cre adenovirus. pStat3,
phosphorylated Stat3 (Tyr705). (C) Immunohistochemistry with antibodies against phosphorylated STAT3 (Tyr705) and STAT3
in pancreata of the indicated genotypes. Mice were treated with tamoxifen and caerulein as indicated in Figure 5A. Scale
bars ¼ 50 mm. n ¼ 3–5 mice analyzed.
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(Supplementary Figure 1A), and STAT3 is known to be
important for oncogenic KRas-induced pancreatic tumor
development.28,29,35 To validate the involvement of this
pathway downstream of YAP1/TAZ, we analyzed the
expression of JAK–STAT3 pathway components in the human
PDAC cell line PANC1, which shows constitutively active
YAP1/TAZ (Supplementary Figure 8B and C). The receptors
LIFR, GP130, IL13RA1, and the transcription factor STAT3
were down-regulated upon YAP1 and TAZ knockdown in
PANC1 cells (Figure 4A). Accordingly, YAP1/TAZ knockdown
reduced STAT3 and LIFR protein levels (Figure 4A and
Supplementary Figure 8D). Overexpression of constitutively
active YAP1-5SA or TAZ-S89A led to increased protein levels
of STAT3 and LIFR in primary mouse acinar cells (Figure 4B
and Supplementary Figure 9A and B).We next tested whether the JAK–STAT3 pathway genes
are direct transcriptional targets of the YAP1/TAZ-
dependent TEAD transcription factors.36 The promoter re-
gions of STAT3, LIFR, and GP130 contain TEAD4 binding
sites, as analyzed by genome-wide ENCODE chromatin
immunoprecipitation experiments37 (Supplementary
Figure 9C). We conﬁrmed that TEAD4 binding was signiﬁ-
cantly enriched at the promoters of STAT3, LIFR, and GP130
by chromatin immunoprecipitation (Figure 4C). In the
STAT3 promoter region, one TEAD consensus binding site
GT-IIc38 was found 312 bp to 306 bp upstream of the STAT3
transcription start site (Figure 4D). We used the entire
STAT3 promoter region including this site in a luciferase
reporter construct transfected into the rat pancreatic acinar
cell line AR42J. Overexpression of either YAP1-5SA or TAZ-
S89A in this cell line signiﬁcantly increased the luciferase
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empty vector control (Figure 4D). Mutation of the TEAD
binding site abolished the YAP1- and TAZ-induced luciferase
activity (Figure 4D). Deletion of Stat3 did not change the
expression or protein levels of YAP1 and TAZ in primary
acinar cells (Supplementary Figure 10A–C). Our results
suggest that, through TEAD, YAP1 and TAZ regulate the
gene expression of the cytokine receptors LIFR and GP130
and the transcription factor STAT3.
JAK–STAT3 Pathway Activation in
Acinar-to-Ductal Metaplasia Lesions
To examine whether JAK–STAT3 signaling is involved in
ADM, we analyzed STAT3 activation in response to
caerulein-induced pancreatitis. Caerulein treatment led to
widespread active, phosphorylated STAT3 (pTyr705-STAT3)
in the injured pancreas (Figure 4E), in accordance with
previous reports.29 STAT3 phosphorylation and up-
regulation of STAT3 and LIFR proteins were also detected
in caerulein-treated pancreas lysates (Figure 4F and
Supplementary Figure 10D and E), and Stat3, Lifr, Gp130, and
Jak1 were up-regulated in injured pancreata at the tran-
scriptional level (Figure 4F), in agreement with our bio-
informatic analysis (Supplementary Figure 1A). Co-staining
with CK19 and amylase revealed increased staining in-
tensity of STAT3 and LIFR in KRasG12D-induced ADM cells in
the Pdx1-Cre model (Supplementary Figure 11A and B).
YAP1/TAZ-Dependent Extreme Acinar-to-Ductal
Metaplasia Sensitization by Oncogenic KRasG12D
The up-regulation of the JAK–STAT pathway by YAP1/
TAZ predicted an increased susceptibility of KRasG12D-
mutant acinar cells to inﬂammation, independently of
oncogenic transformation. To test this, we challenged con-
trol (R26-LSL-YFP;Ela1-CreERT2) and R26-LSL-YFP;LSL-
KRasG12D;Ela1-CreERT2 mice with caerulein to induce
pancreatitis (Figure 5A). As expected, control mice treated
with low doses of caerulein showed acinar cell loss,
inﬂammation, and a limited number of ADM lesions. How-
ever, R26-LSL-YFP;LSL-KRasG12D;Ela1-CreERT2 mice displayed
a dramatic increase in ADM lesions double-positive for
amylase and CK19 after caerulein treatment, although the
recruitment of inﬂammatory F4/80-positive macrophages
was similar to caerulein-treated control mice (Figure 5B, C,
and Supplementary Figure 12A). Lineage tracing with the
Cre-inducible R26-LSL-YFP allele conﬁrmed the acinar cell
origin of the ADM lesions (Supplementary Figure 12B).
Thus, oncogenic Ras mutations dramatically increase the
susceptibility of acinar cells to undergo ADM, possibly by
increasing acinar cell sensitivity to inﬂammatory cytokines
through up-regulation of Stat3, Lifr, and Gp130.
We next tested the signiﬁcance of YAP1/TAZ and STAT3
in Ras-induced ADM sensitization directly. Strikingly,
co-deletion of Yap1 and Taz completely blocked the
enhanced formation of these pancreatitis-induced ADM
lesions by KRasG12D (Figure 5B and C). Pancreata of R26-LSL-
YFP;LSL-KRasG12D;Yap1ﬂ/ﬂ;Tazﬂ/ﬂ;Ela1-CreERT2 mice showed
normal morphology with some signs of caerulein-inducedacinar cell loss and inﬂammation similar to the extent
observed in control mice (Figure 5B and Supplementary
Figure 12A). Additionally, in agreement with previous re-
sults,29 loss of STAT3 signiﬁcantly reduced caerulein-
induced CK19-positive ductal structures in the mutant
KRasG12D background (Figure 5B and C). Ras-induced ADM
formation resulted in increased expression of the pancreatic
progenitor marker Pdx1 and the duct marker Sox9, which
was dependent on YAP1/TAZ (Figure 5D and
Supplementary Figure 13A). These results suggest that
expression of KRasG12D in normal, untransformed acinar
cells results in extreme sensitization to pancreatitis-induced
ADM, which is mediated by YAP1/TAZ and STAT3.
JAK–STAT3 Pathway Acts Downstream of
YAP1/TAZ in Response to Oncogenic Ras
and Inﬂammatory Stimuli
We next addressed the function of YAP1/TAZ and JAK-
STAT3 signaling as effectors of oncogenic Ras. KRasG12D
was activated in adult acinar cells using tamoxifen-inducible
LSL-KRasG12D;Ela1-CreERT2 mice, and gene expression was
analyzed 7 days later, when pancreas histology was unal-
tered and no tumor initiation had occurred. KRasG12D acti-
vation in normal untransformed acinar cells resulted in
increased expression of the YAP1/TAZ target genes Ctgf and
Cyr61, accompanied by transcriptional induction of Stat3,
Lifr, and Gp130 (Figure 6A). Importantly, activation of STAT3
pathway genes by oncogenic KRasG12D in this context
occurred without caerulein treatment. After deletion of
Yap1ﬂ/ﬂ;Tazﬂ/ﬂ, KRasG12D was unable to induce YAP1/TAZ
target genes or Stat3, Lifr, and Gp130 expression (Figure 6A).
KRasG12D activation in primary acinar cells in vitro increased
YAP1 and TAZ protein levels, STAT3 protein levels and
STAT3 phosphorylation (Figure 6B and Supplementary
Figure 13B), but deletion of Yap1ﬂ/ﬂ;Tazﬂ/ﬂ modestly
reduced STAT3 protein levels and greatly impaired the
KRasG12D-induced phosphorylation of STAT3 in acinar cells
in vitro (Figure 6B and Supplementary Figure 13B). In
agreement with these results, caerulein treatment of
tamoxifen-induced LSL-KRasG12D;Ela1-CreERT2 mice led to a
dramatic increase in STAT3 phosphorylation at tyrosine 705,
which was completely abolished in the absence of YAP1 and
TAZ (Figure 6C, Figure 5D, and Supplementary Figure 13A).
YAP1 and TAZ deletion also diminished the caerulein-
induced phosphorylation of STAT3 in pancreatic acinar
cells wild type for KRas (Supplementary Figure 14A and B).
These data indicate that, even in the absence of an inﬂam-
matory stimulus or tumorigenesis, oncogenic Ras mutation
leads to YAP1/TAZ and JAK–STAT3 pathway activation, and
YAP1 and TAZ act upstream of the JAK-STAT3 signaling
pathway in oncogenic KRas-induced ADM.
Deletion of YAP1 and TAZ Reduces
Inﬂammation-Induced Ras Activation
Inﬂammatory insults lead to hyperstimulation of onco-
genic Ras activity, and interfering with the inﬂammatory
signaling cascade interrupts this feedback activation.18 We
next tested whether YAP1/TAZ affects oncogenic Ras activity.
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KRasG12D in acinar cells (Supplementary Figure 15A and B), as
shown previously.18 Deletion of Yap1 and Taz in the KRasG12Dbackground reduced Ras activation after caerulein treatment
(Supplementary Figure 15A and B). Overexpression of
constitutively active YAP1 in primary acinar cells increased
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oncogenic Ras by TGFa resulted in a more efﬁcient differen-
tiation of acinar to duct cells in vitro39 (Supplementary
Figure 16A and B). However, YAP1 and TAZ were required
for KRasG12D-induced ADM, even in the presence of TGFa
(Supplementary Figure 16A and B).YAP1 and TAZ Are Required for
KRasG12D-Induced Pancreatic Intraepithelial
Neoplasia Formation
To determine whether the block to ADM in
Yap1ﬂ/ﬂ;Tazﬂ/ﬂ;LSL-KRasG12D;Ela1-CreERT2 mice affects the
development of pancreatic cancer, we assessed PanIN
lesions 3 months after the transient induction of
pancreatitis by caerulein (Figure 7A). At this stage,
LSL-KRasG12D;Ela1-CreERT2 mice displayed CK19/amylase
double-positive ADM lesions and CK19- and AB/PAS-positive
PanIN lesions (Figure 7B–D). Yap1 and Taz co-deletion
resulted in a striking decrease in ADM lesions and these
mice were free of PanIN lesions, similar to control mice
(Figure 7B–D). These results show that acinar cell-speciﬁc
YAP1/TAZ signaling is essential for oncogenic KRasG12D-
induced PanIN formation in the context of pancreatitis, and
that STAT3 signaling appears to be a critical downstream
factor in this process.BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
PA
NC
RE
ASDiscussion
Acinar-to-ductal reprogramming is now established as
an important precursor to PanIN lesions and progression to
pancreatic cancer, but the molecular mechanisms that drive
this process have remained unclear. Our results conﬁrm that
KRasG12D mutation synergizes with inﬂammatory insults to
induce widespread and persistent ADM lesions, and we
elucidate how this synergy occurs (Figure 7E). We ﬁnd that
the transcriptional regulators YAP1 and TAZ are required
for KRasG12D to promote acinar-to-ductal reprogramming,
both in vitro and in vivo. In the absence of YAP1 and TAZ,
KRasG12D is unable to induce PanIN lesions, suggesting that
acinar-to-ductal reprogramming via YAP1/TAZ is an obli-
gate step in pancreatic cancer initiation from acinar cells.
Mechanistically, active YAP1 and TAZ interact with the
transcription factor TEAD, which binds and up-regulates the
expression of several genes in the JAK–STAT3 pathway. This
pathway controls the response to inﬂammatory cytokines
like IL6, which is secreted during caerulein-induced
pancreatitis and also present at high levels in pancreatic
tumors, promoting PanIN progression in KRasG12D mice.35,40=
Figure 7. YAP1 and TAZ are required for KRasG12D-induced P
induced PanIN formation in the KRasG12D background. (B) H
acid–Schiff (AB/PAS) stains of pancreata from mice of the indica
double immunoﬂuorescence ¼ 50 mm; AB/PAS (4th row) ¼
CK19þamylaseþ ADM lesions in control, LSL-KRasG12D;Ela1-C
n ¼ 3–4 mice per genotype; means ± SEM are shown; *P < .05
lesions in control, LSL-KRasG12D;Ela1-CreERT2, and LSL-KRasG1
means ± SEM are shown; *P < .05, Student t test. (E) Schem
initiation by inducing ADM in response to oncogenic KRasG12DA recent study found that the IL6 co-receptor GP130,
up-regulated by YAP1/TAZ in our study, also activates YAP1
independently of STAT3.41 Additionally, LIFR has been
shown to act upstream of YAP1 signaling.42 This would
create a positive feedback loop amplifying YAP1 activity.
Our data in mouse models expressing KRasG12D are
consistent with ﬁndings in cultured cells showing that Ras
signaling both stabilizes and activates YAP1.43,44 Recent
studies have implicated YAP1 as an important driver of
pancreatic cancer progression at later stages in collaboration
with oncogenic Ras, and as a mechanism of escape from Ras-
RAF-MEK-targeted therapies.19,20,45 However, data from pa-
tient samples has shown that the incidence of KRas codon 12
mutations is already>90%, even in the earliest pre-neoplastic
lesions.8 Here we show that YAP1 acts downstream of onco-
genic Ras at this early reprogramming stage. There is likely
redundancy between YAP1 and TAZ because co-deletion of
Yap1 and Taz is more efﬁcient in blocking KRasG12D- induced
ADM in the in vitro assay compared with either single mutant.
YAP1 seems able to compensate for TAZ deletion but not vice
versa, however, overexpression of constitutively active YAP1
or TAZ alone is sufﬁcient to induce ADM.
We noted that inactivation of YAP1 and TAZ reduced
ADM formation more efﬁciently than Stat3 deletion
(Figure 5). It has been shown that the Hippo pathway also
interacts with other signaling pathways that have implica-
tions in ADM, such as Wnt and Notch pathways.23,46 YAP1/
TAZ-dependent regulation of these pathways might also
contribute to ADM formation.
The presence of the KRasG12D mutation in ADM cells in an
inﬂammatory microenvironment is known to be sufﬁcient
for progression to PanIN lesions and pancreatic cancer.1
Additionally, inﬂammation in the pancreas creates a feed-
back loop leading to hyperactivation of oncogenic KRasG12D
(Figure 7E).18 The KRasG12D mutation and subsequent
hyperactivation promotes pancreatic cancer at 2 levels: it
creates a susceptible “cell of origin” by inducing acinar-to-
ductal reprogramming; and it also acts as the transforming
driver that enables progression toward malignancy. This
model explains why KRas mutations in pancreatic cancer are
so common, and why they frequently appear very early, as a
gatekeeper mutation, in pancreatic acinar cells.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2016.05.006.anIN. (A) Scheme showing experimental design of caerulein-
&E, amylase, and CK19 antibody, and Alcian Blue/periodic
ted genotypes. Scale bars: H&E ¼ 200 mm; CK19 ¼ 200 mm;
200 mm; AB/PAS (5th row) ¼ 50 mm. (C) Quantiﬁcation of
reERT2 and LSL-KRasG12D;Yap1ﬂ/ﬂ;Tazﬂ/ﬂ;Ela1-CreERT2 mice.
, Student t test. (D) Quantiﬁcation of AB/PAS-positive PanIN
2D;Yap1ﬂ/ﬂ;Tazﬂ/ﬂ;Ela1-CreERT2 mice. n ¼ 3–4 mice per group;
e showing the roles of YAP1 and TAZ in pancreatic cancer
and inﬂammation. See text for details.
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